Two diketopiperazines, XR334 (1) and the novel compound XR330 (2), were isolated from the lyophilised biomass of an unidentified Streptomyces sp. Their structures were elucidated on the basis of spectroscopic studies and confirmed by chemical synthesis. Both compounds inhibited plasminogen activator inhibitor-1 activity in an amidolytic assay of tissue plasminogen activator mediated plasmin generation. Compound1 also enhanced fibrinolysis ex vivo and protected against thrombus formation in the rat. These diketopiperazines represent the first low molecular weight inhibitors of plasminogen activator inhibitor-1, a physiological regulator of fibrinolysis protein including a 23 amino acid signal peptide with a predicted, glycosylated mass of 52 kD3). PAI-1 inhibition of tPA is mediated through a "bait" residue (Arg 346-Met 347) which mimics the normal substrate40. The physiological importance of PAI-1 has been demonstrated in transgenic mice which express high levels of human PAI-1 and suffer severe venous thrombosis5). An increase in the plasma concentration of PAI-1 has been proposed as a risk factor in thrombotic disease6). During a screening programme for inhibitors of PAI-1 activity we discovered a series of low molecular weight, nonpeptidyl inhibitors of PAI-1 from fermentation of an unidentified Streptomyces sp. Twoexamples of this series, XR334 (1) and the novel compound XR330 (2) were purified from the mycelium7) (Fig. 1) . A series of closely related metabolites has been isolated from Streptomyces thioluteus including 18). Several of these compounds were reported to show weak antibacterial activity. Synthetic analogues of 1 have also been reported previously9~11}. Related diketopiperazines with putative cytotoxic activity have also been isolated from Micromonospora neiheunsis12). Wereport here an important new biologi- Structures of 1 and 2 isolated from the culture biomass of Streptomyces sp. and the structure confirmed by synthesis. Structures for two additional minor metabolites, 3 and 4, are proposed.
Two diketopiperazines, XR334 (1) and the novel compound XR330 (2), were isolated from the lyophilised biomass of an unidentified Streptomyces sp. Their structures were elucidated on the basis of spectroscopic studies and confirmed by chemical synthesis. Both compounds inhibited plasminogen activator inhibitor-1 activity in an amidolytic assay of tissue plasminogen activator mediated plasmin generation. Compound1 also enhanced fibrinolysis ex vivo and protected against thrombus formation in the rat. These diketopiperazines represent the first low molecular weight inhibitors of plasminogen activator inhibitor-1, a physiological regulator of fibrinolysis Thrombotic and thromboembolic diseases are major causes of hospitalisation and death in the developed world. A key event in the regulation of thrombus formation and clearance is tissue plasminogen activator (tPA) generation of plasmin1}. tPA activity is itself regulated primarily by the fast-acting inhibitor plasminogen activator inhibitor-1 (PAI-1), a member of the serine protease inhibitor (serpin) super family of protease inhibitors2). The PAI-1 CDNAencodes a 402 amino acid protein including a 23 amino acid signal peptide with a predicted, glycosylated mass of 52 kD3). PAI-1 inhibition of tPA is mediated through a "bait" residue (Arg 346-Met 347) which mimics the normal substrate40. The physiological importance of PAI-1 has been demonstrated in transgenic mice which express high levels of human PAI-1 and suffer severe venous thrombosis5). An increase in the plasma concentration of PAI-1 has been proposed as a risk factor in thrombotic disease6). During a screening programme for inhibitors of PAI-1 activity we discovered a series of low molecular weight, nonpeptidyl inhibitors of PAI-1 from fermentation of an unidentified Streptomyces sp. Twoexamples of this series, XR334 (1) and the novel compound XR330 (2) were purified from the mycelium7) ( Fig. 1) . A series of closely related metabolites has been isolated from Streptomyces thioluteus including 18). Several of these compounds were reported to show weak antibacterial activity. A cryovial containing lml of a suspension of biomass of Streptomyces sp. X01/4/100 in 10% glycerol was retrieved from storage at -135°C and 0.5ml of this used to inoculate 20ml of medium S in a 250-ml Erlenmeyer flask. MediumS consisted of D-glucose, malt extract, yeast extract, glycerol, soyabean peptone, NaCl, CaCO3, Junlon PW100 (Honeywill & Stein), Tween 80 (Sigma), pH 7. This culture was incubated at 28°C on an orbital shaker at 240rpm for 4 days before another 20ml of mediumS was added and the incubation was continued under the same conditions for a further 4 days. At this point the 40ml culture was used to inoculate 3.5 litres of mediumS in a 4.5-litre stirred fermenter which was then incubated at 28°C, 350rpm for 4 days with an aeration rate of 0.5 volumes of air per volume of fermentation per minute (vvm). The pH of this culture was controlled to between 5.5 and 6.5. The resultant culture was used to inoculate 50 litres of medium P in a 75-litre stirred fermenter. Medium P contained MOPS, proline, carried out for 5 days at 28°C with stirring at 250~500 rpm and aeration at 0.5vvm, the pH was controlled at between 5.75 and 6.5 and antifoam A (Sigma) was used to control foaming.
Effect of Concentration of MediumP on Production of 1 and 2 Small scale (10ml) cultures were used to investigate howthe concentration of mediumand C : N ratio affected the production of these metabolites. The results shown in Fig. 2 clearly show that reduction in the concentration of mediumP had a stimulatory effect on the production of both 1 and 2. Reduction of the medium concentration to 75%or 50%that of the control led to 2.96 and 2.4 fold increases respectively in the production of 2 (Fig. 2b) , the increase in production in 75% mediumresulting in a 2 fold increase in product titre despite a reduced biomass. The effect on specific production of 1 was far more marked with 45.5 and 43-fold increases observed with 75% and 50% medium concentrations respectively (Fig. 2a ). This increase in the production of these metabolites maybe linked to the greater availability of oxygen per unit biomass in the diluted media. Observations from the large scale fermentations of this organism (data not shown) support this hypothesis. The highest titres were achieved in cultures where the dissolved oxygen tension (DOT) remained above 50%.
Effect of C:N Ratio on Production of 1 and 2 Fermentations were carried out using variations of 75%medium P with C : N ratios increased or decreased from the original value of 13.8 : 1. The modifications were made through increasing or decreasing the concentra- OCT. 1996 Fig. 3. Production of1 and 2.
Maximummeasured titres over 1 10 hours on media with different C : N ratios.
tions of sucrose and glycerol in the medium,concentrations of all other mediumcomponentsremained constant. Fig. 3 shows the maximumtitre of 1 and 2 obtained in the different media after 1 10 hours. A reduction in the C:N ratio from 13.8: 1 decreased the titres achieved, whereas increasing it to 27 : 1 increased the titres. The decreasedtitresatthelowerC: Nratios(9.1 : 1 and7.2 : 1) correlated well with a reduction in the production rate of the metabolites (data not shown). In contrast, the higher C:N ratio media did not increase the initial production rate but these conditions appeared to delay cell lysis which resulted in a prolonged production phase (data not shown). The optimumC:N ratio for this system was 27.1 : 1 as a further increase in the ratio led to a lower production rate and a lower titre at harvest.
Isolation
Compounds1 and 2 were isolated from the mycelium by solvent extraction and purified by chromatography. Details of the isolation procedure are described in the experimental section.
Physico-chemical
Properties and
Structure Elucidation
The compounds were characterised by standard physical techniques, including UV, MS, IR and NMR spectra. The physico-chemical properties of 1 and 2 are summarised in Table 2 . The 13C and XH NMRdata of 2 are summarised in Table 3 .
In the case of compound2 a molecular formula of C20H18N2O3 was deduced from accurate mass measurements on the molecular ion. The XHand^^H COSY NMRspectra included two three-proton singlets corresponding to the presence of two methyl groups attached proposed to be 3Z, 6Z based on the geometric isomer produced by S. thioluteus and biosynthetic grounds. The proposed structures of 1 and 2 were confirmed by synthesis. Synthesis of 1 and 2 The synthesis of compounds 1 and 2 is outlined in Fig.  5 . Details of the synthesis are described in the experimental section.
Biological Activity Chromogenic Assays
Compounds 1 and 2 inhibited PAI-1 in an in vitro tPA-mediated plasmin generation assay (S2251) with IC50 values of 51±7/jm (mean+SE) and ca. 30fiM, respectively. Compound1 was chosen to profile further and was shown to also inhibit PAI-1 in a urokinase amidolytic assay (S2444) with an IC50 value of 80 ± 4 fiM. Various controls were included to exclude the possibility that the diketopiperazine interfered with the substrates or acted directly on the plasminogen activators. Details of these assays are described in the experimental section.
Rat Dilute Blood Clot Lysis Time Assay
The effect of1 on ex vivo fibrinolysis in the rat is shown in Fig. 6 .
Discussion
The diketopiperazines described in this paper provide a chemical template for the design of low molecular weight inhibitors of PAI-1. The two related metabolites, including the novel compound2, were isolated from the lyophilised biomass of an unidentified Streptomyces sp. It is probable that this family of diketopiperazine adducts are derived from phenylalanine and O-methyltyrosine.
The structures of 1 and 2 were confirmed by total OCT. 1996 synthesis.
As part of a programmeto identify additional active metabolites we assessed the effect of mediumcomponent concentration and C : N ratio on production of 1 and 2. Dilution of the growth medium resulted in increased production of both compounds but the increase was greater for 1. It is probable that increased oxygen availability contributed to the enhanced production. A marked improvement in titre for both 1 and 2 was achieved by increasing the C:N ratio from 13.8: 1 to 27.1 : 1. Additional related metabolites were isolated from the biomass. The proposed structures (XR333, 3, and XR335, 4) are shown in Fig. 1 but there was insufficient material for full structural confirmation.
There is a growing body of evidence that elevated PAI-1 activity is a risk factor for thromboembolic disease as a result of decreased fibrinolytic activity15). The importance of PAI-1 is supported by recent studies utilising antibodies as PAI-1 inhibitors. In a rabbit jugular vein model an anti-PAI-1 monoclonal antibody was shown both to promote thrombolysis and to limit thrombus growth16). In a second study a fragment of a polyclonal antibody against PAI-1 was reported to increase flbrinolysis17).
Compounds 1 and 2 inhibited PAI-1 activity in an amidolytic assay of tPA-mediated plasmin generation. These results were not due to a direct effect on tPA as the compounds did not enhance tPA activity in the absence of PAI-1. Although both compounds were poorly soluble in aqueous media 1 was selected for further evaluation as a higher concentration could be achieved. In a second amidolytic assay 1 also reversed the inhibitory effects ofPAI-1 on urokinase and these data implied that the diketopiperazine was modulating the PAI-1: serine protease interaction possibly through interaction with the PAI-1 protein. In the light of the limited solubility of 1 the estimated IC50 values may be an underestimate due to precipitation of the compound in the in vitro assay buffer. Importantly 1 also enhanced fibrinolysis in an ex vivo assay of clot lysis in whole rat blood following intravenous bolus administration demonstrating that activity was retained in a more complex physiological medium18). Compound 1 dose dependency increased clot lysis in blood from animals treated with the diketopiperazine compared to the vehicle group (Fig. 6) P<0.01). Compound1 had comparable activity in this modelto an infusion of the reference compoundaspirin, which inhibits platelet aggregation. Importantly 1 at high concentration (100 /im) had no effect on human platelet aggregation stimulated by collagen, ADP and sodium arachidonate (data not shown 
Isolation of 1 and 2
A 50 litre fermentation was centrifuged and the supernatant discarded. The resulting mycelium (ca. 10 kg wet weight) was mixed briefly with methanol to remove any excess supernatant and then extracted with dichloromethane-methanol mixture (1 : 1) followed by dichloromethane. The extracts were pooled and evaporated under reduced pressure to dryness (ca. 10 g).
A column (internal diameter 3.5 cm, depth 25 cm) was slurry packed with'silica gel (Baker, 40 to 60/mi) in hexane. A solution of the crude extract in dichloromethane was dispersed in silica gel, the solvent removed and the remaining material applied to the column and eluted using a stepwise hexane/dichloromethane/ethyl acetate/methanol gradient increasing from 0%hexane to 100%methanol; 50 x 50ml fractions were collected. The fractions were concentrated to dryness, redissolved in 1 %dichloromethane/methanol (volume varied from 5 to 15ml) and monitored by high performance liquid chromatography and for PAI-inhibitory activity and those fractions containing the diketopiperazines were combined and concentrated to dryness. and the assay performed essentially by the method outlined above. Inhibition of PAI-1 activity resulted in cleavage of the chromogenic substrate S2444 (GluGlu-Arg-pNAà"HC1) by urokinase and release of pnitroaniline.
Rat Dilute Blood Clot Lysis Time (DBCLT)
The ex vivo DBCLT assay was performed as described18*. Either vehicle (10% Solutol in 0.9% saline) or 1 (1, 2.5 or 5mg/kg) was administered by single bolus injection via the tail vein to male Wistar rats. A blood sample was collected after 2.5 minutes, diluted 1 : 4 then (3Z)-l-Acetyl-3-(4-methoxybenzylidene)-2,5-piperazinedione (6) A solution of l ,4-diacetyl-2,5-piperazinedione (5) (1 0 g, 50.5 mmol) and 4-methoxybenzaldehyde (6.14ml, 50.5 mmol) in dry tetrahydrofuran (100ml) was cooled to 0°C. A solution of potassium /-butoxide (5.67g, 50.5mmol) in /-butanol (100ml) was then added dropwise over 30 minutes. After the addition was complete the mixture was allowed to warm to room temperature overnight. The mixture was diluted with ethyl acetate (400 ml) and washed with water (2 x 200 ml) and saturated brine (2 x 200ml). The white precipitate which formed in the organic phase during this process was filtered off and dried to give 9.55g (69%) (3Z)-l -Acetyl-3-(4-methoxybenzylidene)-4-methyl-2,5-piperazinedione (7) A mixture of (3Z)-l -acetyl-3-(4-methoxybenzylidene)-2,5-piperazinedione (6), methyl iodide (1.71 ml, 27.4 mmol) and sodium carbonate (1.93 g, 18.25mmol) in dry dimethylformamide (100ml) was stirred at room temperature for 4 days. After 4 days TLC (ethyl acetate:
hexane 1 : 1) indicated that no starting material remained. The mixture was diluted with ethyl acetate (750ml) and washed with saturated brine (4 x 300ml). 
